Information
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and it...
Original sourceAI Summary
Fortress Biotech's subsidiary Cyprium Therapeutics has secured a $205 million deal by selling a Priority Review Voucher after the FDA approval of ZYCUBO for Menkes disease. This transaction, alongside potential royalties, positions Fortress to reach profitability in the near term.
Sentiment Rationale
The $205 million PRV sale enhances Fortress' liquidity and develops a clearer path to profitability, similar to profitable exits seen previously in biotech companies that leverage strategic assets effectively.
Trading Thesis
FBIO shares are likely to see upward momentum due to the PRV sale enhancing financial stability.
Market-Moving
- The $205 million sale significantly boosts Fortress' cash reserves.
- Profitability expectations could drive positive market sentiment for FBIO.
- Potential royalties on ZYCUBO sales may enhance future earnings.
- Closing conditions may add uncertainty but are expected to be met.
Key Facts
- Cyprium Therapeutics sold a PRV for $205 million.
- ZYCUBO was approved by the FDA on January 12, 2026.
- Fortress expects to reach profitability this year.
- Cyprium can earn royalties and development milestones from Sentynl Therapeutics.
- The transaction is subject to customary closing conditions.
Companies Mentioned
- Cyprium Therapeutics (CYPR): Sold PRV which strengthens financial position.
- Sentynl Therapeutics (SENT): Assumed commercialization of ZYCUBO, impacting Cyprium's revenue stream.
- Fortress Biotech (FBIO): Parent company benefiting from subsidiary transactions and potential profitability.
Corporate Developments
This transaction aligns with 'Corporate Developments' as it involves strategic asset management through a significant sale aimed at enhancing financial strength and positioning for future growth.